On February 11, 2022, it was determined that Dolca Thomas, M.D. would cease serving as the Company's Executive Vice President of Research & Development and Chief Medical Officer and separate from the Company effective as of February 25, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.46 USD | +4.29% | -5.81% | +101.94% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+101.94% | 49.36M | |
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Equillium, Inc. Announces Cessation of Dolca Thomas as Executive Vice President of Research & Development and Chief Medical Officer